These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16623000)

  • 1. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study.
    Kwanngern K; Tiyapattanaputi P; Wanitpukdeedecha M; Navicharern P
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S42-5. PubMed ID: 16623000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study.
    De Palma GD; Catanzano C
    Am J Gastroenterol; 1999 Apr; 94(4):982-5. PubMed ID: 10201469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors.
    Christoforidis E; Goulimaris I; Kanellos I; Tsalis K; Demetriades C; Betsis D
    Endoscopy; 2002 Apr; 34(4):286-92. PubMed ID: 11932783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
    Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
    Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.
    Sotoudehmanesh R; Khatibian M; Kolahdoozan S; Ainechi S; Malboosbaf R; Nouraie M
    Am J Gastroenterol; 2007 May; 102(5):978-83. PubMed ID: 17355281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
    Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
    Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis.
    Sudhindran S; Bromwich E; Edwards PR
    Br J Surg; 2001 Sep; 88(9):1178-82. PubMed ID: 11531863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
    Budzyńska A; Marek T; Nowak A; Kaczor R; Nowakowska-Dulawa E
    Endoscopy; 2001 Sep; 33(9):766-72. PubMed ID: 11558030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
    Lee KT; Lee DH; Yoo BM
    Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
    Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
    Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial.
    Dumot JA; Conwell DL; O'Connor JB; Ferguson DR; Vargo JJ; Barnes DS; Shay SS; Sterling MJ; Horth KS; Issa K; Ponsky JL; Zuccaro G
    Am J Gastroenterol; 1998 Jan; 93(1):61-5. PubMed ID: 9448176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
    Cheon YK; Cho KB; Watkins JL; McHenry L; Fogel EL; Sherman S; Schmidt S; Lazzell-Pannell L; Lehman GA
    Gastrointest Endosc; 2007 Dec; 66(6):1126-32. PubMed ID: 18061712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
    Sternlieb JM; Aronchick CA; Retig JN; Dabezies M; Saunders F; Goosenberg E; Infantolino A; Ionna S; Maislin G; Wright SH
    Am J Gastroenterol; 1992 Nov; 87(11):1561-6. PubMed ID: 1279967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis.
    Kapetanos D; Kokozidis G; Christodoulou D; Mistakidis K; Sigounas D; Dimakopoulos K; Kitis G; Tsianos EV
    Gastrointest Endosc; 2007 Sep; 66(3):513-8. PubMed ID: 17725940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis?: a retrospective, multicenter study.
    Deenadayalu VP; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Temkit M; Lehman GA; Sherman S
    J Clin Gastroenterol; 2008; 42(10):1103-9. PubMed ID: 18936645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
    Kaffes AJ; Bourke MJ; Ding S; Alrubaie A; Kwan V; Williams SJ
    Gastrointest Endosc; 2006 Sep; 64(3):351-7. PubMed ID: 16923481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis.
    Dumot JA; Conwell DL; Zuccaro G; Vargo JJ; Shay SS; Easley KA; Ponsky JL
    Am J Gastroenterol; 2001 Jul; 96(7):2098-102. PubMed ID: 11467638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography.
    Duvnjak M; Supanc V; Simicević VN; Hrabar D; Troskot B; Smircić-Duvnjak L; Bekavac-Beslin M
    Acta Med Croatica; 1999; 53(3):115-8. PubMed ID: 10705631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.